Acquired Hemophilia Treatment Market up-to-date analysis of industry trends and Growth Prospect forecast to 2025
                     Adroit Market Research
Global Acquired Hemophilia Treatment Market 
Size 2018
by Therapy (Inhibitor Eradication Therapy and 
Hemostatic Therapy), by Region and Forecast 2019 to 
2025
Single Use License: US$ 4400 Request Sample
+1 (214) 884-6068               [email protected] www.adroitmarketresearch.com
Adroit Market Research
Acquired Hemophilia Treatment Market Size to reach 
$2,700.9 million by 2025
• The global acquired hemophilia treatment market is set to reach USD 2,700.9 million by 
2025, growing at a CAGR of 3.1%. The clinical manifestation associated with acquired hemophilia 
is provoked or spontaneous unexplained bleeding with delayed activated partial thromboplastin 
time (aPTT) in patients with no previous hereditary association with coagulopathy. Researchers 
throughut the globe are actively enaged in developing guidelines for the accurate diagnosis of 
acquired hemophilia due to its overlapping clinical manifestations with other autoimmune disease. 
The exorbitant cost associated with the bypassing agents employed as hemostatic therapy to 
control bleeding episodes will hamper the acquired hemophilia treatment market growth.
• The treatment of acquired hemophilia comprises two pronged approach, control incessant bleeding 
episodes and subsequently reducing the inhibitor titer against clotting factor VIII in the blood 
serum. Physicians worldwide usually prefer bypassing agents such as FEIBA and NovoSeven RT for 
managing major bleeding complications in hemorrhage of vital internal organs. Desmopressin and 
Obizur are employed to counter minor bleeding complications due to hemorrhage of peripheral 
blood vessels by increasing the circulating blood plasma levels of clotting factor VIII in the human 
body. Eradication inhibitor therapy comprises first line agents of alone or drug combination of 
prednisolone and immunosuppressant such as cyclophosphamide, azathioprine etc., to reduce the 
inhibitor titer volume against clotting factor VIII. Monoclonal antibodies such as rituximab and 
emicizumab are used as second line inhibitor eradication therapy in patients showing resistant to 
steroid and cytotoxic agents.
Browse the complete report on @ 
+1 (2h14tt) p88s4:-/6/06w8 w     w    .  a   [email protected]/industry-rewpwowr.atdsr/oaitmcqarukeitrreesde-ahrceh.mcomophilia-treatment-marke
t
 
Adroit Market Research
Acquired Hemophilia Treatment Market Size to reach $2,700.9 million 
by 2025
• North America is currently dominating the regional segment for acquired hemophilia treatment 
market. The key parameters responsible for its supreme market growth are rising public health 
awarness regarding autoimmune disease leading to early disease diagnosis and treatment. 
• As per the latest research findings brought forward by the Center for Disease Control and 
Prevention (CDC), the prevalence rate of acquired hemophilia in the United States is 0.2 to 1 per 
million people. Affordable reimbursement scenario for medicines employed for treating acquired 
hemophilia in federally funded hemophilia care centers will further strenghten the market growth in 
the region. 
• Europe represents 31.8% market share on account of presene of key players such as Baxter 
Healthcare Corporation, Shire, Plc., Novo Nordisk and GlxoSmithkline, Plc., wich determines the 
market growth in the region. Asia Pacific holds 16.4% market share and is keen to register rampant 
growth during the forecast period on account of rising prevalence of acquired hemophilia in elderly 
population and developing healthcare infrastructure.
• The key biopharmaceutical companies actively  engaged in the manufacturing of drugs employed 
for the treatment of acquired hemophilia are Baxter Healthcare Corporation, BioXcel Corporation, 
Genetech, Inc., GlaxoSmithkline, Plc., Ferring B.V., Mylan N.V., Novo Nordisk, Sanofi SA, Shire, Plc. 
and Teva Pharmaceutical Industries Ltd.
+1 (214) 884-6068               [email protected] www.adroitmarketresearch.com
Adroit Market Research
Key segments of the global acquired hemophilia treatment 
market
Therapy Type Overview, 2015-2025 (USD Million)
• Inhibitor Eradication Therapy
• Steroids
• Cytotoxic Agents
• Immunomodulatory Agents
• Hemostatic Therapy
• Desmopressin
• Recombinant Activated Factor VII/NovoSeven RT
• Recombinant Activated Factor VIII/Obizur
•  Activated Prothrombin Complex Concentrate (aPCC)/FEIBA
Purchase a single user copy of the global acquired hemophilia treatment Market report@ 
https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1037 
+1 (214) 884-6068               [email protected] www.adroitmarketresearch.com
Adroit Market Research
About Us
Adroit Market Research is an India-based business analytics and consulting company. Our 
target audience is a wide range of corporations, manufacturing companies, product/technology 
development institutions and industry associations that require understanding of a market’s 
size, key trends, participants and future outlook of an industry. We intend to become our 
clients’ knowledge partner and provide them with valuable market insights to help create 
opportunities that increase their revenues. We follow a code– Explore, Learn and Transform. At 
our core, we are curious people who love to identify and understand industry patterns, create 
an insightful study around our findings and churn out money-making roadmaps. Our analysts 
have tracked high growth markets in chemicals & materials, healthcare & pharmaceuticals, 
semiconductor & electronics, energy & power, food & retail, consumer goods, technology, and 
machinery & equipment sectors across the world to identify new opportunities, potential 
customers, prepare go-to-market (GTM) strategies, identify segments for revenue growth for 
Contact Us companies, and many more.
US Headquarters Phone: +1 (214) 884-6068
Email: [email protected]
3131 McKinney Ave Ste 600 Dallas, 
TX 75204 ,U.S.A 
+1 (214) 884-6068               [email protected] www.adroitmarketresearch.com